

RESPONSE TO ELECTION OF SPECIES REQUIREMENT
U.S. Appln. No. 10/643,384

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Currently Amended) A method for treating infection in a patient having an infection, comprising administering to said patient a composition comprising Flt3-ligand, wherein the Flt3-ligand comprises an amino acid sequence that is at least 90% identical to amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235, and wherein the Flt3-ligand binds Flt3.

Claim 2. (Original) The method of claim 1, wherein the infection is bacterial.

Claim 3. (Original) The method of claim 1, wherein the infection is viral.

Claim 4. (Original) The method of claim 1, wherein the Flt3-ligand comprises amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235.

Claim 5. (Original) The method of claim 1, wherein the Flt3-ligand comprises amino acid residues 28-160 of SEQ ID NO:2.

Claim 6. (Original) The method of claim 1, wherein the Flt3-ligand comprises amino acid residues 28-182 of SEQ ID NO:2.

Claim 7. (Original) The method of claim 1, wherein the Flt3-ligand stimulates the proliferation of hematopoietic stem and/or progenitor cells.

Claim 8. (Original) The method of claim 1, wherein the Flt3-ligand stimulates the proliferation of cells selected from

RESPONSE TO ELECTION OF SPECIES REQUIREMENT
U.S. Appln. No. 10/643,384

the group consisting of myeloid precursor cells, monocytic cells, macrophages, B-cells, T-cells and dendritic cells.

Claim 9. (Currently Amended) A method of increasing the number of dendritic cells in a patient having an infection, comprising administering to said patient a composition comprising Flt3-ligand, wherein the Flt3-ligand comprises an amino acid sequence that is at least 90% identical to amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235, and wherein the Flt3-ligand binds Flt3.

Claim 10. (Original) The method of claim 9, wherein the infection is bacterial.

Claim 11. (Original) The method of claim 9, wherein the infection is viral.

Claim 12. (Original) The method of claim 9, wherein the Flt3-ligand comprises amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235.

Claim 13. (Original) The method of claim 9, wherein the Flt3-ligand comprises amino acid residues 28-160 of SEQ ID NO:2.

Claim 14. (Original) The method of claim 9, wherein the Flt3-ligand comprises amino acid residues 28-182 of SEQ ID NO:2.

Claim 15. (Currently Amended) A method of augmenting immune responses in a patient having an infection, comprising administering to said patient a composition comprising Flt3-ligand, wherein the Flt3-ligand comprises an amino acid sequence that is at least 90% identical to amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235, and wherein the Flt3-ligand binds Flt3.

Claim 16. (Original) The method of claim 15, wherein the infection is bacterial.

RESPONSE TO ELECTION OF SPECIES REQUIREMENT
U.S. Appln. No. 10/643,384

Claim 17. (Original) The method of claim 15, wherein the infection is viral.

Claim 18. (Original) The method of claim 15, wherein the Flt3-ligand comprises amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235.

Claim 19. (Original) The method of claim 15, wherein the Flt3-ligand comprises amino acid residues 28-160 of SEQ ID NO:2.

Claim 20. (Original) The method of claim 15, wherein the Flt3-ligand comprises amino acid residues 28-182 of SEQ ID NO:2.

Claim 21. (Original) The method of claims 1, 9 or 15, wherein the Flt3-ligand further comprises a pharmaceutically suitable carrier, diluent and/or preservative.

Claim 22. (Original) The method of claims 1, 9 or 15, wherein the Flt3-ligand is complexed with polyethylene glycol.

Claim 23. (Original) The method of claims 1, 9 or 15, wherein the Flt3-ligand is administered topically, parenterally or by inhalation.